NOVO NORDISK A/S vs DR REDDYS LABORATORIES LIMITED & ANR.

Judgment text excerpt

$~ * IN THE HIGH COURT OF DELHI AT NEW DELHI Reserved on: 19 January 2026 Pronounced on: 9 March 2026 + FAO(OS) (COMM) 204/2025 & CM APPL. 78607/2025 NOVO NORDISK A/S .....Appellant Through: Mr. Hemant Singh, Ms. Mamta Jha, Mr. Rishabh Paliwal, Mr. Shreyansh Gupta, Mr. Sanchit Sharma, Advs. versus DR REDDYS LABORATORIES LIMITED & ANR. .....Respondents Through: Mr. Gopal Subramanium, and Mr. J. Sai Deepak, Sr. Advs. with Mr. Mohit Goel, Mr. Sidhant Goel, Mr. Aditya Goel, Mr. Deepankar Mishra, Mr. Kartikeya Tandon, Mr. Pavan Bhushan, Mr. Avinash Sharma, Mr. Raghav Kohli, Mr. Adnan Yousuf and Mr. Ankit Malhotra, Advs. CORAM: HON'BLE MR. JUSTICE C. HARI SHANKAR HON'BLE MR. JUSTICE OM PRAKASH SHUKLA JUDGMENT % 09.03.2026 C. HARI SHANKAR, J. A. Some prefatory thoughts 1. This case makes us ponder, and we have said so in open Court. Signature Not Verified Digitally Signed By:AJIT KUMAR FAO(OS) (COMM) 204/2025 Page 1 of 34 Signing Date:09.03.2026 16:58:32 2. The dispute relates to a patent held by the appellant for Semaglutide, which is an anti-diabetic. The appellant claims that, in December 2024, it came to learn that the respondents were importing Semaglutide. On the ground that said import infringed the appellant’s patent, the suit, from which this appeal emanates, came to be instituted only in 2025. The suit was accompanied, as such suits always are, with an application seeking an interlocutory injunction restraining the respondents from manufacturing or selling Semaglutide in the Indian market. That application was rejected by the learned Single Judge on 2 December 2025, by a detailed and well-reasoned judgment. The appellant is in appeal. 3. Thus far, we have no issue. What perturbs us is the fact that this appeal has been preferred when the suit patent itself is to expi